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Abstract: Previously-designed amphiphilic scorpion-like macromolecule (AScM) nanoparticles
(NPs) showed elevated potency to counteract oxidized low-density lipoprotein (oxLDL) uptake
in atherosclerotic macrophages, but failed to ameliorate oxLDL-induced inflammation. We designed
a new class of composite AScMs incorporating lithocholic acid (LCA), a natural agonist for the
TGR5 receptor that is known to counteract atherosclerotic inflammation, with two complementary
goals: to simultaneously decrease lipid uptake and inhibit pro-inflammatory cytokine secretion by
macrophages. LCA was conjugated to AScMs for favorable interaction with TGR5 and was also
hydrophobically modified to enable encapsulation in the core of AScM-based NPs. Conjugates were
formulated into negatively charged NPs with different core/shell combinations, inspired by the
negative charge on oxLDL to enable competitive interaction with scavenger receptors (SRs). NPs
with LCA-containing shells exhibited reduced sizes, and all NPs lowered oxLDL uptake to <30%
of untreated, human derived macrophages in vitro, while slightly downregulating SR expression.
Pro-inflammatory cytokine expression, including IL-1β, IL-8, and IL-10, is known to be modulated
by TGR5, and was dependent on NP composition, with LCA-modified cores downregulating
inflammation. Our studies indicate that LCA-conjugated AScM NPs offer a unique approach to
minimize atherogenesis and counteract inflammation.
Keywords: atherosclerosis; amphiphile; TGR5; lithocholic acid; nanoparticle; inflammation; macrophages
1. Introduction
Cardiovascular disease is the leading global cause of death, claiming approximately 17.3 million
lives and costing upwards of $860 billion annually [1]. Innovative methods for prevention and
treatment of cardiovascular disease are needed to decrease its prevalence. Many vascular conditions
begin with atherosclerosis, an inflammatory cascade culminating in the accumulation of atherosclerotic
lesions and calcified plaques in the arterial vasculature [2]. In atherogenesis, circulating monocytes are
recruited in response to subendothelial retention of apolipoprotein B and oxidative modification of low
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density lipoproteins (oxLDL). Macrophages, differentiated from strongly adherent monocytes, become
lipid laden foam cells as they internalize oxLDL via two primary scavenger receptors (SRs), SR-A
and CD36 [3,4]. Excessive and unregulated oxLDL internalization ultimately results in macrophage
apoptosis, and ineffective clearance of cellular debris initiates plaque formation around a necrotic core
leading to adverse cardiovascular events [4].
Statins represent the most commonly prescribed class of cholesterol-lowering pharmaceuticals.
Statins function via competitive inhibition of HMG-CoA reductase, the rate-limiting step of cholesterol
biosynthesis, and subsequently upregulate low density lipoprotein (LDL) receptors [5,6]. Although
they exhibit substantially decreased hepatic and circulating cholesterol levels, systemic administration
and off-target effects prove detrimental [7,8]. HMG-CoA reductase inhibition also affects synthesis
of natural products synthesized downstream of cholesterol (e.g., bile acids, sex-steroids), as well
as crucial parallel biosynthetic pathways (e.g., coenzyme Q10) [8]. As such, strategically targeted
approaches to ameliorate atherosclerosis are needed, including techniques to lower the recruitment
of monocytes, inhibit the deposition and accumulation of circulating LDL and atherogenic lipids at
lesion sites, and counteract the athero-inflammatory cascade that leads to lesion growth.
Amphiphilic scorpion-like macromolecules (AScMs) designed in our group have been shown
to attenuate atherosclerotic outcomes [9–14]. AScMs are comprised of a linear sugar backbone with
fatty acid pendants conjugated to poly(ethylene glycol) (PEG), which self-assemble into nanoscale
micelles at low concentrations (~10−6 M). These unique compounds can successfully encapsulate
and deliver anti-atherosclerotic therapeutics to macrophages, increasing drug bioavailability [11,15].
Furthermore, the AScMs exhibit inherent bioactivity against several cell types (e.g., macrophages and
smooth muscle cells) involved in the atherosclerotic cascade when formulated into either micelles or
kinetically trapped nanoparticles (NPs), which are advantageous due to their resistance to dissociation
upon dilution [16–18]. NPs have demonstrated additional superiority to micelle formulations as
AScM NPs lower macrophage oxLDL uptake to ~25% relative to untreated controls, decrease SR
expression, and reduce plaque size and aortic occlusion in vivo [17,19,20]. AScMs mode of action
occurs via competitive inhibition of oxLDL uptake by SRs due to columbic interactions between
the negative charge on NPs and the positive charge in SR binding pockets [13]. Investigation into
interactions between differentially oxidized LDL and AScM NPs indicate negligible interactions and
support this primary mode of action [10]. Despite their promise for treating early stage atherosclerosis,
the lead NP formulation, consisting of a 1cM shell and M12 core (Figure 1), fails to ameliorate the
inflammatory component of atherosclerosis that can exacerbate the disease state [18]. Thus, new AScM
designs are necessary to not only counteract atherogenesis, but also mitigate the accompanying
inflammatory cascade.
Recent approaches to mitigate this effect include using anti-inflammatory molecules, such as
Vitamin E, as the NP core component; however, these NPs exhibit compromised oxLDL uptake
inhibition at low administration concentrations, and this strategy does not target the intrinsic
inflammatory responses accompanying oxidized lipid uptake [18]. An alternate preventative approach
is to target inherent biological lipogenic pathways that combat the inflammatory response induced
by both the NPs and the atherosclerotic cascade. The G-protein coupled bile acid receptor 1
(GPBAR-1, also known as TGR5), known for its anti-inflammatory implications in the digestive
tract, is an emerging target in mediating pro-inflammatory cytokines in atherosclerosis due to its high
expression in both monocytes and macrophages [21]. Activation of TGR5 reportedly reduces monocyte
adhesion in endothelial cells, stabilizes the alternative M2 phenotype, and inhibits lesion formation
in vivo [21–24]. Lithocholic acid (LCA) is a naturally occurring secondary bile acid resulting from
the dehydroxylation of chenodeoxycholic acid, and activates TGR5 at 0.53 µM [21]. LCA, which is
present in serum in its free and conjugated forms, has the strongest activation of TGR5 compared
to other naturally occurring bile acids such as deoxycholic acid, chenodeoxycholic acid, and cholic
acid. Furthermore, LCA has demonstrated suppressed lipopolysaccharide (LPS)-stimulated cytokine
production and has anti-atherogenic implications [25]. Hence, conjugation of LCA to AScMs could
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decrease the inherent inflammation associated with AScM NP administration and provide benefits of
activating a target implicated in anti-atherogenic outcomes both in vitro and in vivo.
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Figure 1. Chemical structures and schematics of shell and core molecules incorporated into NPs via flash
nanoprecipitation. Chemical structures of 1cM and 1cMLCA shells and M12 and alkylLCA cores and
corresponding cartoons (A). R group refers to dodecyl ester (top left) in all chemical structures. Schematic
representation of the flash nanoprecipitation technique utilized to generate amphiphilic scorpion-like
macromolecule (AScM) nanoparticles (NPs) using 1cMLCA[alkylLCA] as an example (B) where the
poly(ethylene glycol) (PEG) components (blue lines) extend into aqueous media from the shell and
lithocholic acid (LCA) (green circles) is encapsulated within the core of the NP. Nomenclature of 1cM
refers to 1 carboxylic acid (1c) on a mucic acid backbone (M), and M12 nomenclature refers to a mucic acid
backbone (M) with dodecyl alkyl chains (12).
Here, we report the synthesis of LCA-conjugated NP components and describe their bioactivity
in human macrophages in vitro. LCA-conjugated constructs were strategically designed based on the
hypothesis that native esterases would cleave AScMs and act as depots that release LCA to interact
with TGR5 without compromising the anti-atherogenic effects of the AScM NPs. NP formulations with
unique core/shell combinations were evaluated for the components’ influence on NP physicochemical
properties, as well as the ability to inhibit oxLDL uptake and lower macrophage inflammation.
2. Materials and Methods
2.1. Materials
All reagents and materials were purchased from Sigma-Aldrich (Milwaukee, WI, USA) and were used
as received unless noted otherwise. Hydrochloric acid (HCl, 1 N) was purch sed from Fisher Scientific
(Fair Lawn, NJ, USA), and silica from VWR (Radnor, PA, USA). The confined impinging jet mixer was
provided by Prof. Robert Prud’homme at Princeton University (Princeton, NJ, USA). Cell culture assays
used human buffy coats purchased from the New York Blood Ce ter (New York, NY, USA) or New Jersey
Blood Center (East Orange, NJ, USA), Ficoll-P que premium 1.077 g/mL and Percoll 1.3 g/mL from
GE Healthcare (Fairfield, CT, USA), FEP Teflon cell culture bags from Cellgenix, RPMI-1640 from ATCC
(Manassas, VA, USA), macrophage colony stimulating factor (MCSF) from Pepr Tech (Rocky Hill, NJ, USA),
penicillin/streptomycin fro Lonza (Basel, Switzerland), fetal bovine serum (FBS) from Life Technologies
(Carlsbad, CA, USA), human serum from MP Biomedical, unlabeled oxLDL from Biomedical Technologies
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Inc. (Ward Hill, MA, USA), and 3,3′-dioctadecyloxacarbocyanine (DiO) labeled oxLDL from Kalen
Biomedical (Montgomery Village, MD, USA).
2.2. Characterization
Proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectra were obtained from
a Varian 400 MHz or 500 MHz spectrometer. Reaction products were dissolved in deuterated
chloroform (CDCl3) with trimethylsilane (TMS) as an internal reference. Fourier transform infrared
(FT-IR) spectra were obtained by solvent-casting small molecules onto sodium chloride (NaCl) plates
in dichloromethane (DCM) then recorded using a Thermo Scientific Nicolet iS10 spectrophotometer
with an average of 32 scans per sample and processed using OMNIC software. Small molecule
molecular weights were established using a ThermoQuest Finnigan (LCQ-DUO system equipped with
a syringe pump, optional divert/inject valve, atmospheric pressure ionization (API) source, and mass
spectrometer (MS) detector) and spectra were processed using the Xcalibur data system. Compounds
(10 µg/mL) were dissolved in methanol (MeOH) or DCM with 1% acetic acid or ammonia for positive
or negative ion detection, respectively. Weight-averaged molecular weights (Mw) and polydispersity
indices (PDI) of AScMs were determined by gel permeation chromatography (GPC) using a Waters
liquid chromatography (LC) system (Milford, MA, USA), equipped with a 2414 refractive index
detector, 1515 isocratic HPLC pump, 717plus autosampler, and Jordi divinylbenzene mixed-bed
GPC column (7.8 × 300 mm, Alltech Associates, Deerfield, IL, USA). Samples (10 mg/mL) were
prepared in DCM and filtered through a 0.45 µm polytetrafluoroethylene (PTFE) syringe filter prior to
autoinjection. The eluent (DCM) was set at a flow rate of 1 mL/min, and IBM ThinkCentre computer
with WaterBreeze version 3.20 software used to process data against a calibration curve generated with
broad-range PEG standards (Waters Milford, MA, USA).
2.3. Synthesis
2.3.1. Synthesis of 1cMLCA (4)
According to a modified literature procedure, the carboxylic acid of LCA was selectively
protected [26]. LCA (1, 1.0 equivalents (eq.)) was dissolved in 10 mL of anhydrous dimethylformamide
(DMF) under nitrogen. Potassium carbonate (1.2 eq.) was added and the suspension allowed to stir for
30 min. Benzyl bromide (1.5 eq.) was then added and the reaction stirred for 12 h at room temperature.
The reaction was diluted with diethyl ether (20 mL) and washed with sodium bicarbonate (3×, 15 mL).
The crude product was dried over magnesium sulfate (MgSO4), filtered, and concentrated in vacuo.
2 was then purified on silica gel via flash chromatography using a hexanes/ethyl acetate gradient (95:5
to 80:20).
1cM, synthesized as previously described [27], was dried by azeotropic distillation with toluene
under reduced pressure 3× prior to use. 1cM (1.0 eq.) was then dissolved in 10 mL of DCM under
nitrogen with 2 (2.0 eq.) and 4-(dimethylamino)pyridinium-4-toluene sulfonate (DPTS, 1.0 eq.) under
nitrogen, followed by dropwise addition of N,N′-dicyclohexylcarbodiimide (DCC, 1 M, 2.0 eq.) as
a coupling reagent. After 24 h, the reaction was cooled to 0 ◦C and the urea byproduct removed via
filtration. The filtrate was washed 2× with 1 N HCl and 1× with brine, followed by removal of solvent
in vacuo. The product was precipitated in diethyl ether (50 mL), collected via centrifugation (3500 rpm,
5 min each) and washed a total of 5× to obtain 3.
The benzyl group was removed via hydrogenolysis with palladium on carbon (Pd/C, 10% w/w)
as the catalyst for 24 h in DCM (10 mL). The heterogeneous mixture was then filtered through Celite to
remove Pd/C and the filtrate removed in vacuo to obtain 4.
Benzyl lithocholate (2): Yield: 76% (white solid). 1H-NMR (500 MHz, CDCl3): δ 0.61 (s, 3H), 0.91 (s, 6H),
0.94–1.93 (br. m, 27H), 2.26 (m, 1H), 2.39 (m, 1H), 3.61 (m, 1H), 5.10 (s, 2H), 7.35 (m, 5H). 13C-NMR
(500 MHz, CDCl3): δ 12.01, 18.23, 20.80, 23.36, 24.19, 26.40, 27.18, 28.16, 30.54, 30.96, 31.27, 34.56, 35.30,
35.34, 35.83, 36.45, 40.15, 40.41, 42.08, 42.71, 55.94, 56.47, 66.07, 71.85, 128.15, 128.21, 128.53, 136.12,
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174.11. IR (cm−1, thin film from chloroform CHCl3): 3334.36 (OH, alcohol), 1736.88 (C=O, ester).
Electrospray ionization-mass spectrometry (ESI-MS) m/z: 505.5 [M + 39]+.
1cM benzyl lithocholate (3): Yield: 78% (white solid) 1H-NMR (500MHz, CDCl3): δ 0.64 (s, 3H), 0.87 (m, 18H),
0.94–1.99 (br. m. 99H), 2.27 (m, 4H), δ 2.41 (m, 4H), 3.63 (m, ~425H), 4.27 (m, 2H), 4.30 (m, 2H), 4.72 (m, 1H),
5.18 (m, 4H), 5.70 (m, 2H), 7.35 (m, 5H). Mw = 5.6, PDI = 1.2.
1cMLCA (4): Yield: 81% (white solid) 1H-NMR (500MHz, CDCl3): δ 0.64 (s, 3H), 0.87 (m, 21H),
0.94–1.99 (br. m. 99H), 2.27 (m, 4H), 2.41 (m, 4H), 3.63 (m, ~425H), 4.27 (m, 2H), 4.30 (m, 2H),
4.72 (m, 1H), 5.18 (m, 2H), 5.70 (m, 2H). Mw = 5.6, PDI = 1.2.
2.3.2. Synthesis of LCA-Based Hydrophobe (7)
2 (1.0 eq.) and zinc chloride (ZnCl2, 0.5 eq.) were dissolved in 10 mL of DCM under N2, followed
by addition of lauroyl chloride (3.0 eq.), then heated to reflux overnight with stirring. The crude
product was then purified using silica gel via flash chromatography with hexanes/ethyl acetate (90:10)
to yield 5.
The benzyl-protecting group was removed via hydrogenolysis as previously described, and the
carboxylic acid of 6 was conjugated to dodecanol via carbodiimide coupling. Dodecanol (2.0 eq.) and
dimethylaminopyridine (DMAP, 2.0 eq.) were completely dissolved in 10 mL anhydrous DCM under
nitrogen. The coupling reagent 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide (EDCI, 2.5 eq.) was
added and the reaction stirred overnight. The mixture was washed with 10% potassium bisulfite
(2×, 15 mL) and brine (1×, 15 mL) to remove the urea byproduct and DMAP. The crude product was
purified on silica gel via flash chromatography with hexanes/ethyl acetate (80:20). The organic layer
was then dried over MgSO4, filtered, and concentrated in vacuo to obtain 7.
Alkylated benzyl lithocholate (5): Yield: 73% (white solid). 1H-NMR (500 MHz, CDCl3): δ 0.61 (s, 3H),
0.88 (t, 3H), 0.91(s, 6H), 0.94–1.93 (br. m, 44H), 2.26 (m, 3H), 2.39 (m, 1H), 4.72 (m, 1H), 5.10 (s, 2H),
7.35 (m, 5H). 13C-NMR (500 MHz, CDCl3): δ 12.01, 14.10, 18.24, 20.82, 22.67, 23.32, 24.16, 25.09, 26.32,
26.69, 27.02, 28.16, 29.12, 29.24, 29.32, 29.45, 29.59, 30.97, 31.28, 31.90, 32.27, 34.59, 34.78, 35.04, 35.31,
35.78, 40.12, 40.39, 41.90, 42.72, 56.00, 56.46, 66.07, 74.05, 128.15, 128.21, 128.52, 136.12, 173.43, 174.08. IR
(cm−1, thin film from chloroform CHCl3): 1735.05 (C=O, ester).
Mono-alkylated lithocholic acid (6): Yield: quantitative (white solid) 1H-NMR (500 MHz, CDCl3): δ 0.64
(s, 3H), 0.88 (t, 3H), 0.92 (s, 6H), 0.94–1.96 (br. m, 44H), 2.26 (m, 3H), 2.39 (m, 1H), 4.72 (m, 1H).
13C-NMR (500 MHz, CDCl3): δ 12.03, 14.10, 18.23, 20.82, 22.67, 23.32, 24.16, 25.09, 26.31, 26.68, 27.01,
28.16, 29.11, 29.24, 29.32, 29.45, 29.58, 29.59, 30.75, 30.82, 31.90, 32.29, 34.58, 34.78, 35.04, 35.30, 35.78,
40.13, 30.39, 41.89, 42.74, 55.97, 56.47, 74.06, 173.48, 179.36. IR (cm−1, thin film from chloroform CHCl3):
1732.86 (C=O, ester), 1703.15 (C=O, acid). ESI-MS m/z: 557.7 [M − 1]−.
Alkylated lithocholate (7): Yield: 86% (white solid) 1H-NMR (500 MHz, CDCl3): δ 0.64 (s, 3H), 0.87
(t, 3H), 0.92–1.96 (br. m, 71H), 2.30 (m, 6H), 4.04 (t, 2H), 4.77 (m, 1H). 13C-NMR (500 MHz, CDCl3): δ
12.02, 14.10, 18.25, 20.82, 22.67, 23.32, 24.17, 25.09, 25.94, 26.34, 26.68, 27.02, 28.17, 28.65, 29.11, 29.24,
29.32, 29.34, 29.45, 29.52, 29.56, 29.58, 29.59, 29.62, 29.64, 31.05, 31.36, 31.91, 32.29, 34.59, 34.78, 35.04,
35.34, 35.79, 40.13, 40.39, 41.90, 42.73, 56.04, 56.47, 64.42, 74.05, 173.44, 174.42. IR (cm−1, thin film from
chloroform CHCl3): 1737.47 (C=O, ester). ESI-MS m/z: 727.5 [M + 1]+.
2.4. Nanoparticle Fabrication
NPs were fabricated via flash nanoprecipitation as previously described [17]. Briefly, the AScM
(40 mg/mL) and hydrophobe (20 mg/mL) were separately dissolved in tetrahydrafuran (THF).
A 1:1 v/v mixture of the AScM:hydrophobe solution (0.5 mL) was filtered through a 0.2 µm PTFE
filter, then rapidly mixed with phosphate buffered saline (PBS, 0.5 mL) in a confined impinging jet
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mixer, and subsequently added to 4.5 mL of PBS. NP suspensions were dialyzed using a 6–8 kDa
ultrafiltration membrane cut-off 3× against sterile PBS (2 L) for organic solvent removal.
2.5. Nanoparticle Characterization
NP sizes and zeta (ζ) potential were measured by dynamic light scattering (DLS) using
a Malvern-Zetasizer Nano Series (ZS90) in triplicate with a 90◦ scattering angle. NPs sizes and
PDI were evaluated in PBS, and the Z-average was taken as the hydrodynamic diameter. Prior to
analyzing ζ potential, NPs were dialyzed extensively against deionized water.
2.6. Isolation of Human Monocyte Derived Macrophages (hMDMs)
Peripheral blood mononuclear cells (PBMCs) were isolated from human buffy coats by
centrifugation through Ficoll-Paque (1.077 g/cm3) density gradient [19]. Red blood cells were lysed
with ammonium-chloride-potassium (ACK) buffer and cell debris, including platelets, were removed
via centrifugation (300× g, 10 min). PBMCs were washed with PBS and cultured in RPMI 1640
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (complete medium).
PBMCs were selected for monocytes as determined by flask adherence after 24 h at 37 ◦C and
5% CO2. Monocytes were cultured for 7 days in complete medium with 50 ng/mL macrophage colony
stimulating factor (M-CSF) to differentiate monocytes into macrophages. hMDMs were trypsinized,
and plated at a density of 150,000 cells/mL and let rest for a minimum of 12 h prior to experimentation.
2.7. Oxidized Low Density Lipoprotein (oxLDL) Uptake in Macrophages
hMDMs were plated in 24 well tissue culture plates at a density of 1.5 × 105 cells/mL and
incubated with unlabeled oxLDL (4 µg/mL) and DiO labeled oxLDL (1 µg/mL) in the presence
of NPs (10−5 M) in complete medium for 24 h, as this concentration was demonstrated to have
>80% cell viability. Treatment and control media were aspirated and replaced with ice-cold PBS
containing 2 mM ethylenediaminetetraacetic acid (EDTA) and plates were placed on ice packs.
Cells and EDTA were triturated to remove cells from plates, centrifuged (1000 rpm, 10 min),
and fixed in 1% paraformaldehyde (150 µL). oxLDL uptake was quantified by fluorescence using
a FACScalibur flow cytometer (Becton Dickenson, Franklin Lakes, NJ, USA) by collecting a minimum
of 10,000 events/sample. Results were analyzed via FlowJo software (Tree Star Inc., Ashland, OR, USA)
and reported as the geometric mean fluorescence intensity (MFI). All experiments were performed in
triplicate and data is presented as percent (%) oxLDL uptake as normalized to the basal control.
2.8. Gene Expression in Macrophages
Gene expression (GAPDH, ACTB, IL-1β, IL-6, IL-8, IL-10, TNFα, CD36, SR-A) in hMDMs was
evaluated using quantitative reverse transcription polymerase chain reaction (qRT-PCR). RNA was
extracted from hMDMs 24 h after treatment using an RNeasy Plus Mini Kit with Quiashredder
columns according to supplier protocol (Qiagen). The concentration and purity of RNA was quantified
using a Nanodrop 2000c. RNA was reverse transcribed to cDNA using a High Capacity cDNA Kit
and RapidCycler thermal cycler (Idaho Technology). RT-PCR was carried out using a Lightcycler
480 (Roche) with Fast SYBR Green Master Mix for 45 cycles. Fold-change was calculated using
∆∆Ct method and normalized to housekeeping genes (actin-β and GAPDH). All forward and reverse
primers were designed by Harvard Primer Bank or Primer-BLAST and synthesized by Integrated
DNA Technology.
2.9. Confocal Microscopy of oxLDL Uptake in Macrophages
Uptake of oxLDL was visualized using confocal microscopy. PBMCs were isolated from human
buffy coats by Ficoll-Paque (1.077 g/cm3) density gradient and Percoll (1.131 g/cm3) density gradient.
PBMCs were collected and washed with PBS-ETDA (1 mM) and plated into FEP Teflon-coated cell
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culture bags at a density of at least 5.0 × 107 monocytes per bag [28]. Monocytes were differentiated
into M2 macrophages using recombinant human M-CSF (2.5 ng/mL) and incubated at 37 ◦C in 5%
CO2 in complete medium for 7 d. After 7 d, culture bags were placed on ice for at least 1 h. The cell
suspension was removed using a syringe, and cells were isolated by centrifugation (400 g, 10 min).
The cells were re-plated at a density of 150,000 cells/mL for at least 12 h prior to treatment. After 24 h
treatment, cells were washed with PBS (pH 7.4, 3×) and fixed with 4% PFA for 20 min. The PFA was
removed and Hoescht dye (0.1 µg/mL) was added for 15 min. Cells were imaged using a Leica TCS
SP8 confocal microscope with a 40× oil immersion objective.
2.10. Statistical Analysis
Statistical analyses were performed using Graph Pad Prism V7.01. Statistical significance was
determined using a one-way ANOVA with Tukey’s posthoc test for comparisons between multiple
groups. Statistical significance of p ≤ 0.05 is indicated in figures.
3. Results and Discussion
3.1. LCA-Conjugates Successfully Synthesized via Multi-Step Reactions
LCA-conjugates were synthesized to evaluate the effect of incorporating a naturally occurring
TGR5 ligand into AScM NP formulations to address atherosclerotic inflammation and mitigate the
proinflammatory effects observed with AScM NP administration. Both an LCA-conjugated AScM and
a hydrophobically modified LCA-conjugate were synthesized to enable the fabrication of NPs with
high LCA incorporation in the shell and core, respectively.
LCA-conjugates were strategically designed to retain oxLDL uptake reduction properties,
while exhibiting the active LCA functionality. We previously observed that AScMs with a net negative
charge resulted in statistically significant reductions in oxLDL uptake compared to neutral or cationic
analogs [9]. The 1cMLCA-conjugate was designed such that LCA would be at the terminal end to
freely interact with TGR5 and bear a net negative charge to mimic the physicochemical properties of
oxLDL for effective SR competitive inhibition and cellular uptake [29]. The carboxylic acid of LCA
(1) was initially protected by reaction with benzyl bromide in the presence of a mild base as shown
in Scheme 1. By doing so, it was assured that the lead AScM from previous studies (1cM) would
be conjugated through the hydroxyl group of 2 via subsequent carbodiimide coupling, yielding the
protected 1cMLCA-conjugate (3). The benzyl protecting group was then removed via hydrogenolysis
with 10% w/w Pd/C to yield the final 1cMLCA-conjugate (4).
A hydrophobic analog of LCA was also synthesized according to Scheme 2 to enable fabrication
of NPs via flash nanoprecipitation. This method combines an amphiphile (e.g., 1cMLCA) and
hydrophobe (e.g., alkylLCA) in a water-miscible organic solvent prior to fabrication. The organic
solution is then rapidly mixed with an aqueous buffer, resulting in hydrophobe precipitation.
The amphiphile assembles around the precipitates, generating NPs with a specific core/shell
architecture (Figure 1B) [30,31]. Although LCA has low aqueous solubility and is capable of forming
NPs with AScMs, the resulting NP stability proved to be insufficient, resulting in rapid NP aggregation
(data not shown). Ansell et al. have previously demonstrated that increasing the hydrophobicity of
partially water-soluble drugs via lipophilic anchor conjugation improves NP formation, extending the
half-life, and thus, bioactivity [32]. To enable efficient encapsulation of LCA and improve NP stability,
the lipophilicity of LCA was increased by first acylating the hydroxyl of 2 in the presence of zinc (II)
chloride to yield 5. Following benzyl deprotection via hydrogenolysis, the free carboxylic acid was
alkylated via carbodiimide coupling to yield the LCA-based hydrophobe, alkylLCA (7) in high purity.
All small molecules were characterized via 1H-NMR, 13C-NMR, and FT-IR spectroscopies and
ESI-MS, while PEGylated products were characterized via 1H-NMR spectroscopy and GPC. Several
techniques, including 1H-NMR and FT-IR spectroscopies were critical to elucidate the final structures
of LCA-conjugates and precursors. Figure 2 presents the sequential 1H-NMR spectra leading to the
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synthesis of 1cMLCA. Successful benzyl protection of LCA’s acid functionality was confirmed via
the absence of the acid carbonyl and the appearance of an ester stretch at 1736.33 cm−1 in the FT-IR
spectrum. Additionally, benzylic and aromatic protons at 5.10 ppm and 7.35 ppm, respectively, in the
1H-NMR spectrum were indicative of successful protection (e and f in Figure 2). Conjugation of 2
to 1cM to generate 3 was evidenced by the relative integration of peaks from 2 and those previously
established to be characteristic of 1cM, as well as the downfield chemical shift of the C3 hydrogen from
3.61 ppm to 4.72 ppm (a in Figure 2). Generation of the final 1cMLCA conjugate (4) was confirmed via
the disappearance of aromatic and benzylic protons in the 1H-NMR spectra.
Techniques including 1H-NMR and FT-IR spectroscopies, and ESI-MS were also crucial in
confirming successful generation of alkylLCA (7). A downfield shift of the C3 hydrogen from 3.61 ppm
to 4.72 ppm and disappearance of the broad –OH stretching vibration in the FT-IR spectrum confirmed
hydroxyl group acylation. Benzyl deprotection was evidenced by the disappearance of benzylic
and aromatic protons (e and f in Figure 3) as previously described, as well as a parent peak in the
ESI-MS at m/z = 557.7 [M − 1]−. Subsequent alkylation of the carboxylic acid was confirmed via the
appearance of a triplet representing the methylene adjacent to the ester at 4.04 ppm (k in Figure 3) and
disappearance of the acid carbonyl in the FT-IR spectra at 1703.15 cm−1.
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3.2. Stable Mono-Dispersed Nanoparticles Fabricated with LCA-Conjugates Possess Negative Charge and Desirable
Size Distributions
Although previous AScM micellar preparations were shown to have bioactivity at high
concentrations, improved inhibition of oxLDL uptake was observed with AScM NPs in
serum-containing medium compared to micelles [16,17]. NPs fabricated using flash nanoprecipitation
are different from micelles in that the core molecule serves as a nucleation point to fabricate kinetically
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trapped particles that do not dissociate upon dissolution. [17] In the present study, novel AScM NPs
were generated via flash nanoprecipitation, including 1cMLCA and alkylLCA as the shell and core
components, respectively. Additional NP formulations with combinations of shell and core materials
were also prepared to evaluate the potential impact of each component on physicochemical properties
and biological outcomes. The previously demonstrated highly efficacious core (i.e., M12) and shell
(i.e., 1cM) materials were included in the evaluation for comparison (Figure 1A).
The physicochemical properties of NP formulations are shown in Table 1. The data demonstrates
that shell composition influences particle size, while core chemistry does not have a significant
influence on any physical attributes. NPs prepared with 1cM shells were found to have statistically
indistinct hydrodynamic diameters, regardless of core identity. Likewise, NPs with 1cMLCA shells
have similar sizes, independent of the core material. However, NPs prepared with 1cM shells have
hydrodynamic diameters that are statistically larger than NPs made with 1cMLCA shells (p ≤ 0.05).
The discrepancy may be due to the differential dynamics of various components during the flash
nanoprecipitation process. This observation suggests that the core materials have similar rates of
precipitation when the molecules contact the aqueous stream during flash nanoprecipitation. However,
the aggregation and packing behavior of the shell material around the precipitated cores appears
to differ due to the addition of the LCA moiety. It is possible that the increased hydrophobicity of
LCA also enhances the packing density of AScMs around the core, therefore leading to the decreased
hydrodynamic diameters of NPs with 1cMLCA shells.
Interestingly, NPs with 1cMLCA shells have sizes below 200 nm, which is the generally accepted upper
limit for cellular uptake via endocytosis [33]. Previous data demonstrated a direct correlation between AScM
NP internalization by cells and an increase in oxLDL uptake inhibition efficacy, and smaller particles have
been shown to be more effectively internalized via endocytosis [17,20,33]. Further, all NPs have comparable
negative ζ potentials, an attribute which appears crucial to NP efficacy for interactions with cationic SRs.
This result correlates with previous data, as NPs with a negative ζ potential are hypothesized to allow
AScM NPs to competitively inhibit oxLDL uptake via coulombic interactions with the positive charge in SR
binding pockets [10,29]. Notably, the addition of LCA does not significantly impact the ζ potential, a feature
that was critical in the molecular design. Further, all NPs have low PDIs, indicating uniform NP size with no
evidence of NP aggregation. This attribute is an important feature to ascertain oxLDL uptake competitive
inhibition and prolonged storage stability.
Table 1. Physicochemical properties of AScM NPs indicating particle size, polydispersity index (PDI)
and ζ potential determined by dynamic light scattering measurements. Formulation notation is denoted
as Shell[Core], and statistical differences are indicated by different symbols.
Formulation Hydrodynamic Diameter (nm) PDI ζ Potential (mV)
1cM[M12] 213 + 4 * 0.11 −30
1cM[alkylLCA] 206 + 16 * 0.09 −31
1cMLCA[M12] 176 + 14 0.16 −33
1cMLCA[alkylLCA] 173 + 2 0.11 −31
3.3. AScM NPs Inhibit oxLDL Uptake in Human Macrophages
To measure oxLDL uptake inhibition, hMDMs were simultaneously treated with AScM NPs
and oxLDL or oxLDL alone (control), and internalization was quantified using flow cytometry and
visualized by confocal microscopy (Figure 4). Cells were treated at 1 × 10−5 M concentration of
the AScMs, as we have previously demonstrated in vitro and in vivo cytocompatibility and high
AScM bioactivity at this concentration [17,19]. Additionally, all AScM NPs described herein have
cytocompatibility >80% (data not shown). Under all AScM NP treatments, oxLDL uptake was
reduced to <30% of controls (Figure 4B). These data demonstrate that both shell materials are
highly efficacious at reducing oxLDL internalization, including NPs with LCA-conjugation. We have
previously demonstrated that NPs based on polystyrene and poly(lactic acid) are inactive [17,20].
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As such, control experiments utilizing NPs with experimental shells and a polystyrene core, as well as
NPs with a polystyrene-PEG shell and experimental cores were carried out. These experiments indicate
that both experimental components are, in fact, active. This observation supports our hypothesis that
the NPs competitively inhibit SRs, including those with LCA conjugation, while they retain potent
oxLDL uptake inhibition properties. The NPs with LCA’s free carboxylate retain a negative ζ potential
and have sizes amenable to endocytosis, which would give rise to potent oxLDL competitive inhibition.
These observations are in agreement with previous findings for other formulations, in which NPs
with weakly negative ζ potentials exhibited poor inhibition of oxLDL uptake compared to NPs with
higher magnitudes of negative ζ potential [20]. Therefore, with the criteria of a negative NP ζ potential
and NP sizes below 200 nm, it is plausible that an array of naturally active ligands conjugated to 1cM
would elicit desired biological effects.
While all shells were found to be active, these data further illustrate that shell chemistries that contain
the 1cM base structure do not adversely influence the magnitude of oxLDL uptake inhibition (Figure 4B).
Both the 1cM and 1cMLCA shells exhibit comparable degrees of oxLDL uptake inhibition. Interestingly,
the NP core material influences the degree of oxLDL uptake, with alkylLCA cores exhibiting significantly
more oxLDL uptake inhibition than M12 cores (Figure 4B). The stronger influence of the core material on
the NP anti-atherogenic potential is consistent with previously reported data using mixed PS and M12
cores [20]. As such, we hypothesize that oxLDL uptake is not only lowered by competitive interactions
with SRs. Rather, it is likely that surface molecules from the NPs’ shells exist in an equilibrium with the
unimeric components. This equilibrium may be mediated by extracellular serum disruption or intracellular
mechanisms, which leads to interactions between the core materials and biological targets. For example,
1cMLCA[alkylLCA] NPs may partly dissociate to free their respective amphiphilic unimers, thereby allowing
them to interact with proximal cellular receptors, such as TGR5, to elicit an enhanced reduction in oxLDL
uptake (Figure 4A). We have demonstrated the biodegradation of AScM ester functionalities by serum
esterases in previous work, which presumably would lead to high local concentrations of free LCA upon
cleavage of alkylLCA [34]. The high local concentration of LCA is hypothesized to be partially responsible
for increased oxLDL reduction for NPs with alkyl LCA cores, as TGR5 activation has a demonstrated effect
on reducing oxLDL uptake [22].
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Figure 4. AScM NPs inhibit oxLDL uptake in macrophages (schematic, A). All NPs lower oxLDL uptake
in hMDMs compared to basal controls as measured via flow cytometry and indicated with (*) (B) Core
chemistry has a significant impact on oxLDL uptake inhibition levels, but shell chemistry does not
significantly alter efficacy as indicated by letters. Bars with different letters represent statistical differences.
Confocal microscopy images of oxLDL uptake by hMDMS 24 h after treatment with AScM NPs cell nuclei
(DAPI, blue), and DiO labeled oxLDL (DiO, green) 40×magnification (C).
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3.4. AScM NP Composition Markedly Impacts Inflammatory Gene Transcription
Gene expression was used to evaluate the LCA-based NPs potential to decrease inflammation
in macrophages. LCA-conjugates were strategically designed to interact with membrane bound
receptors, including TGR5, to mitigate the inflammatory response caused by the atherosclerotic cascade,
as well as from NP administration. TGR5 is a transmembrane protein expressed in macrophages
that has a demonstrated role in the reduction of several inflammatory cytokines in the atherosclerotic
cascade. Of interest, decreases in the transcription and expression of IL-1β, IL-6, and IL-8 have been
demonstrated upon treatment with bile acids or synthetic TGR5 agonists [25,35,36]. These genes are
also upregulated in human macrophages following treatment with 1cM[M12] NPs, which limits this
NP formulation’s clinical applicability [18]. As such, qRT-PCR was utilized to evaluate the potential
influence of NP composition on the inflammatory cytokine profile in human macrophages, including
those genes known to mitigate and exacerbate the disease state.
The simultaneous treatment of macrophages with AScM NPs and oxLDL resulted in changes in
mRNA expression of inflammatory cytokines mediated by TGR5 and SRs involved in oxLDL uptake
(Figure 5). Findings are consistent with previous studies, indicating that NPs containing an M12
core significantly upregulate mRNA expression of the pro-atherogenic cytokine IL-1β [18]. IL-1β is
a pro-inflammatory cytokine secreted by activated monocytes and macrophages and is implicated
in both the early and late stages of atherosclerosis [37]. In the early stages of atherosclerosis, IL-1β
increases adhesion molecule expression in endothelial cell membranes, while in later stages, it facilitates
fibrous cap destabilization at plaque sites in vivo, ultimately leading to plaque rupture [37,38]. As such,
the increase in IL-1β transcription induced by 1cM[M12] NPs is undesirable, and treatment with these
NPs would exacerbate atherogenesis. In this work, the increase in IL-1β observed after 1cM-based
NP treatment was significantly lower with alkylLCA incorporation into the NPs cores as compared to
those with M12 cores (Figure 5). This effect was also observed for NPs with 1cMLCA shells. These data
demonstrate that core modification can mitigate the limitations of previous AScM NP formulations.
We hypothesized that LCA-incorporation into the shell would further downregulate IL-1β expression
due to TGR5 activation. Interestingly, it was observed that the attenuation of IL-1β transcription with
1cMLCA shells was not as prominent, suggesting that inflammation resulting from NP treatment is
multifactorial, and more largely influenced by the hydrophobe component of NPs. As 1cMLCA-based
NPs exhibit a minimal response to core identity, it is possible the overall NP hydrophobicity also
contributes to IL-1β expression.
1cM[M12] also results in upregulation of the pro-atherogenic cytokines IL-6 and IL-8 in macrophages,
limiting its further development as a comprehensive therapeutic against athero-inflammation [18]. IL-6
has been implicated in recruitment of activated monocytes and their subsequent differentiation into
macrophages, and an increase in IL-8 upregulates endothelial expression of adhesive molecules that
promote activated monocyte/macrophage attachment [38]. Both of these steps occur in the early stages of
atherosclerosis, and preventing or reducing their occurrence is crucial to halting the cascade’s initiation and
perpetuation. As such, the reduction in the secretion of these cytokines is needed to increase the therapeutic
potential of AScM NPs. Expression of IL-6 and IL-8 with AScM NP treatment reveal similar trends to those
observed for IL-1β, with a decrease in transcription when macrophages are treated with 1cM-based NP
formulations with alkylLCA cores. Interestingly, no notable trend is observed for expression of either IL-6
or IL-8 in macrophages treated with 1cMLCA NPs, further supporting the hypothesis that the level of
overall AScM NP hydrophobicity is critical in mitigating the inflammatory response in macrophages treated
with NPs.
Additional inflammatory cytokines were evaluated including IL-10 and TNFα, as well as two
SRs responsible for oxLDL internalization, CD36 and SRA. In all cases, NP formulations had minimal
influences on these genes’ mRNA expression. These data suggest that the AScM NPs’ molecular
mechanism leading to inflammation reduction may occur via an alternative mechanism to mRNA
control of protein expression, consistent with previous work demonstrating transient effects on
macrophage cytokines [11]. Nonetheless, 1cM[alkylLCA] was identified as a lead NP formulation,
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as it demonstrates a large reduction in several inflammatory cytokines, namely IL-1β, IL-6, and IL-8,
induced via atherosclerosis and administration of previous AScM NP formulations.
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4. Conclusions
LCA was modified and effectively incorporated into NPs to establish a new generation of NPs for
the treatment of inflammation in atherosclerosis. The NPs were comprised of an LCA-containing shell,
where the bile acid was conjugated to AScMs known to limit uncontrolled oxLDL uptake in human
macrophages, and an LCA-containing core, where LCA was hydrophobically modified to serve as
a NP nucleation point [10]. The appropriate size for cellular uptake and net negative charge allow the
NPs to act similarly to oxLDL and inhibit its uptake via competition with oxLDL in SR binding sites.
NPs with alkylLCA cores lowered the atherogenic potential of macrophages by significantly
decreasing oxLDL uptake compared to NPs with M12 cores. However, the shell composition did not
influence oxLDL uptake inhibition, indicating that the core exerts an active effect over the efficacy. It is
likely that AScM NPs exist in equilibrium with monomeric components, and serum proteases partly
degrade the hydrophobic cores. We hypothesize that this equilibrium would result in interactions
between the natural ligand, LCA, with TGR5, resulting in receptor activation and a decrease in oxLDL
uptake. Both the core and shell components did, however, impact the gene transcription profile in
macrophages treated with AScM NPs. Treatment with 1cM[alkylLCA] NPs resulted in the lowest
mRNA expression levels of inflammatory cytokines in macrophages treated with AScM NPs to date.
Together, this information illustrates that modifying AScM NP composition can have a pronounced
impact on the inflammatory profile of human macrophage populations. The inflammatory cytokines
evaluated in this study that were transcriptionally downregulated in the presence of the 1cM[alkylLCA]
are, in part, regulated by TGR5 activation. It is therefore possible that this NP formulation activates
TGR5, leading to a decrease in inflammation. As it appears that the overall hydrophobicity influences
the inflammatory response, this formulation also appears to have the optimal balance of hydrophobicity
imparted by alkyl chains and LCA moieties to not exacerbate inflammation while simultaneously reducing
inflammatory cytokine expression involved in atherosclerosis.
These findings illustrate that our current class of AScM nanotherapeutics can be modified using
complementary ligands to further fine-tune desired biological outcomes without compromising
the inherent anti-lipogenic profile of previous AScM NPs. As both a reduction in oxLDL uptake
and inflammation are critical to ameliorate macrophage atherogenic potential, the results of these
experiments demonstrate improvement upon previous AScM generations with respect to inflammatory
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cytokine expression and provide insight to develop future AScM NPs that exhibit desirable outcomes
by influencing biological targets.
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